Recombinant bacterium for producing heparin precursor as well as construction method and application of recombinant bacterium

The heparin precursor synthesis pathway was optimized through genome-scale metabolic network models and target prediction algorithms, especially by knocking out the ptsG gene and enhancing the expression of heparin precursor synthetase, which solved the problem of low yield of heparin precursor synthesis strains and achieved efficient and safe heparin precursor production.

CN120775757APending Publication Date: 2025-10-14TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410402390.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-03
Publication Date
2025-10-14

AI Technical Summary

Technical Problem

The yield of heparin precursor synthesis strains in existing technologies is low, and existing transformation strategies fail to effectively improve the yield and conversion rate of heparin precursors, posing biosafety risks and high production costs.

Method used

By establishing a genome-scale metabolic network model and using the FSEOS target prediction algorithm to identify key targets, in particular, the expression of ptsG, a key component in the phosphoenolpyruvate sugar phosphotransferase system (PTS), was knocked out or weakened, combined with enhancing the expression of heparin precursor synthases KfiA, KfiC and KfiD to optimize the heparin precursor synthesis pathway.

Benefits of technology

The yield and conversion rate of heparin precursors were significantly improved, the production of by-products acetic acid and lactic acid was reduced, the production cost was lowered, and safe and efficient heparin precursor synthesis was achieved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to a recombinant bacterium for producing a heparin precursor as well as a construction method and application of the recombinant bacterium. According to the invention, by knocking out or reducing a phosphoenolpyruvate sugar phosphotransferase PTS system of a heparin precursor producing strain, glucose transport, glycolysis and TCA circulation rate are balanced, and generation of by-products acetic acid and lactic acid is reduced, so that more carbon metabolism enters a heparin precursor synthesis pathway, and the yield of heparin precursor is improved. According to the invention, heparin precursor synthetases KfiA (UDP-GlcNAc glycosyl transferase), KfiC (UDP-GlcA glycosyl transferase) and KfiD (UDP-glucose dehydrogenase) are further enhanced, the expression of UDP-GlcA generated by UDP-Glc is catalyzed, and the yield and / or conversion rate of the heparin precursor can be further improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular relates to a recombinant bacterium producing a heparin precursor and a construction method and application thereof. Background Art

[0002] Heparin, a sulfated glycosaminoglycan, is widely used clinically as an anticoagulant. Currently, it is primarily extracted and produced from porcine intestinal mucosa, posing potential risks of contamination and adulteration. The use of microbial production of heparin precursors, followed by a series of enzyme-catalyzed processes to produce bioengineered heparin, offers a potentially safer alternative to animal-derived heparin.

[0003] Heparin precursor (also known as heparinogen, heparosan) is a natural acidic polysaccharide composed of repeating disaccharide units D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine (GlcNAc). It is naturally present in bacteria such as Escherichia coli K5 (Escherichia coli K5), Pasteurella multocida (Pasteurella multocida), and Escherichia coli Nissle 1917 (EcN). In order to produce heparin precursor, it has been reported that the yield of E. coli K5 reached 15g / L through fermentation optimization (E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor, Biotechnol Bioeng. 2010 Dec 15; 107(6):964-73). However, E. coli K5 is a urinary tract pathogen and is biosafe. The heparin precursor produced by it is not suitable for direct use in drug synthesis. The biosynthesis pathways for UDP-GlcA and UDP-GlcNAc, important precursors of heparin precursors, are naturally present in non-pathogenic bacteria such as Escherichia coli and Bacillus. By introducing the heparin precursor synthase KfiAC from Escherichia coli K5 or PmHS1 (or PmHS2) from Pasteurella multocida, safe production of heparin precursors can be achieved. However, existing transformation strategies mainly focus on increasing the expression of heparin precursor enzymes and simultaneously enhancing the expression of genes related to the UDP-GlcA and UDP-GlcNAc biosynthesis pathways, but the yield is still low. For example, overexpression of kfiABCD in Escherichia coli BL21 resulted in a shake flask yield of 334 mg / L (Metabolic engineering of Escherichia coli BL21 for biosynthesis of heparosan, a bioengineered heparin precursor, Metab Eng. 2012 Sep; 14(5): 521-7). Therefore, it is necessary to further optimize heparin precursor synthesis strains through metabolic engineering to increase heparin precursor yield and / or conversion rate and promote green biomanufacturing of heparin. Summary of the Invention

[0004] The present invention addresses the problem of low yield of heparin precursor synthesis strains, systematically analyzes the entire process of the heparin precursor synthesis pathway, and the intermediate metabolites are also involved in multiple metabolic pathways such as material energy metabolism (glycolysis pathway EMP, tricarboxylic acid cycle TCA, pentose phosphate pathway PPP, etc.), cell wall synthesis, lipopolysaccharide (LPS) synthesis, etc. These pathways are extremely complex and affect the production of heparin precursors while being closely related to cell growth. Knocking out related competing pathways may cause cells to be unable to grow or grow poorly. Even if the heparin precursor pathway is strengthened, it may not be possible to ultimately increase the heparin precursor production and / or conversion rate, and the experimental period is long and the cost is high.

[0005] The above-mentioned synthetic pathway and intermediate metabolic pathway involve nearly 50 targets. Based on the genome-scale metabolic network model independently established by the laboratory in the early stage, the present invention calculates the targets that may affect the high production of heparin precursors through the FSEOS target prediction algorithm, including 11 targets such as ptsG, manA, wecB, and nagB. The number of targets that need to be verified is reduced by nearly 5 times, greatly improving the experimental efficiency.

[0006] Model predictions suggest that modifications to the following targets may increase heparin precursor production and / or conversion. Acetate and lactate are the main byproducts produced during the fermentation of heparin precursors by heparin precursor-producing strains. The PTS is the primary active transport system involved in glucose transport from the interstitial membrane and phosphorylation into the intracellular space. The gene encoding the key component, EⅡCBGlc, is ptsG. This system influences the rate of glucose transport, consuming one phosphoenolpyruvate per glucose molecule transported to produce pyruvate, which can lead to intracellular accumulation of pyruvate and the formation of byproducts such as acetate and lactate. The protein encoded by manA catalyzes the conversion of fructose-6-phosphate (F-6-P) to mannose-6-phosphate (Man6P), also competing with the heparin precursor synthesis pathway for fructose-6-phosphate. Glucosamine-6-phosphate is a key intermediate metabolite in the UDP-GlcNAc and heparin precursor synthesis pathways. The protein encoded by nagB catalyzes the conversion of glucosamine-6-phosphate to fructose-6-phosphate. The wecB-encoded protein catalyzes the conversion of UDP-GlcNAc to UDP-ManNAc, competing with the heparin precursor synthesis pathway for UDP-GlcNAc.

[0007] The present invention further verified the effects of these targets on heparin precursor synthesis through genetic modification and activity experiments. The results showed that knocking out manA, wecB, and nagB alone did not increase heparin production and / or conversion rate, while modifying the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS), that is, knocking out or weakening the PTS system, more preferably, knocking out or reducing the key component EⅡCB in the PTS system. GlcThe expression of the coding gene ptsG is controlled to balance the rates of glucose transport, glycolysis and TCA cycle, avoid pyruvate accumulation, reduce by-products, and improve carbon source utilization. Knocking it out can significantly increase the production of heparin precursors and / or improve the conversion rate, ultimately completing the present invention.

[0008] The present invention provides a genetically engineered bacterium for synthesizing a heparin precursor, which is obtained by using a strain capable of synthesizing a heparin precursor as a starting strain and knocking out or weakening the phosphoenolpyruvate sugar phosphotransferase (PTS) system; preferably, the knocking out or weakening of the phosphoenolpyruvate sugar phosphotransferase (PTS) system refers to knocking out or reducing the key component EⅡCB in the PTS system. Glc The expression of the coding gene ptsG.

[0009] The starting bacteria of the present invention are strains having a natural heparin precursor synthesis pathway, or strains into which exogenous KfiAC or PmHS1 or PmHS2 are introduced on the basis of the UDP-GlcA and UDP-GlcNAc synthesis pathways; preferably, the starting bacteria are Escherichia coli, Pasteurella multocida, Bacillus, or Corynebacterium glutamicum; more preferably, the starting bacteria are Escherichia coli K5, Escherichia coli Nissle 1917, Escherichia coli K12, Escherichia coli BL21, Escherichia coli W3110, or Escherichia coli MG1655.

[0010] Furthermore, the present invention also includes enhancing the expression of one, two or three genes of heparin precursor synthase KfiA (UDP-GlcNAc glycosyltransferase), KfiC (UDP-GlcA glycosyltransferase) and KfiD (UDP-glucose dehydrogenase, catalyzing UDP-Glc to produce UDP-GlcA), or enhancing the expression of heparin precursor synthase PmHS1 and / or PmHS2; preferably, the heparin precursor synthase KfiA, KfiC and KfiD are derived from Escherichia coli EcN or Escherichia coli K5, and PmHS1 or PmHS2 is derived from Pasteurella multocida.

[0011] The present invention provides a method for constructing the above-mentioned genetically engineered bacteria.

[0012] The knockout or reduction of gene expression described in the present invention refers to knocking out genes by gene editing methods, and reducing gene expression refers to reducing the transcription level of genes by replacing promoters, or replacing ribosome binding sites, replacing the start codon ATG with GTG or TTG to reduce gene expression at the translation level; or knocking out genes by gene editing methods.

[0013] The gene editing method of the present invention is to knock out a gene using the CRISPR / Cas9 knockout system; more preferably, the N20 sequence complementary to the gene target sequence used in knocking out the ptsG gene is TAACGATGGCGTATCCGCGC.

[0014] The enhanced expression of the present invention is achieved by introducing an overexpression plasmid, or replacing a strong promoter to enhance gene transcription, or replacing a strong RBS sequence to enhance gene expression, or adding an enhancer to increase the gene transcription level.

[0015] Specifically, the overexpression plasmid of the present invention can be pTrc99a, pET, pQE, pBAD, pACYC184, pACYCDuet-1, pRSFDuet-1, etc.

[0016] The present invention also provides the use of the genetically engineered bacteria, or the genetically engineered bacteria obtained by the construction method, in synthesizing heparin precursors.

[0017] The present invention further provides a method for synthesizing a heparin precursor, which comprises fermenting the genetically engineered bacteria to produce the heparin precursor; optionally, further comprising the step of separating or purifying the produced heparin precursor;

[0018] Specifically, the separation or purification method of the heparin precursor is as follows: taking the fermentation broth, adding a final concentration of 0.02% SDS, heating at 95°C for 15 minutes, and then centrifuging at 12,000g for 10 minutes to remove the precipitate; adding 3-4 times the volume of anhydrous ethanol to the supernatant, keeping warm at -20°C for 4-16 hours, and centrifuging at 12,000g for 10 minutes to collect the flocculent precipitate. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Schematic diagram of the biosynthetic pathway of heparin precursors.

[0020] Figure 2 This is a statistical chart of the results of the EcN△G-ACD strain culture in a 5L fermenter. DETAILED DESCRIPTION

[0021] The present invention is further described below with reference to specific examples in order to better understand the present invention, but the present invention is not limited thereto.

[0022] Explanation of terms

[0023] ptsG: EⅡCB, a key component in the PTS system Glc In the embodiment, the coding gene is exemplified by NCBI ID: WP_000475719.1.

[0024] UDP-Glc: UDP-glucose.

[0025] UDP-GlcA: UDP-glucuronic acid is one of the important precursors for the synthesis of heparin precursors.

[0026] UDP-GlcNAc: UDP-N-acetylglucosamine is one of the important precursors for the synthesis of heparin precursors.

[0027] Heparin precursor synthetase: an enzyme that catalyzes the glycosyl transfer between UDP-GlcNAc and UDP-GlcA to synthesize heparin precursors, including KfiAC from Escherichia coli K5 (KfiA is a UDP-GlcNAc glycosyltransferase, KfiC is a UDP-GlcA glycosyltransferase, and these two enzymes are encoded by the kfiA and kfiC genes, respectively), and PmHS1 and PmHS2 from Pasteurella multocida (PmHS1 and PmHS2 are both bifunctional enzymes with UDP-GlcNAc glycosyltransferase and UDP-GlcA glycosyltransferase activities).

[0028] Heparin precursor: also known as heparinogen, English name is heparosan.

[0029] Materials and Methods

[0030] 1. Escherichi coli Nissle 1917 (EcN): from the German Culture Collection DSMZ, number 115365

[0031] 2. Plasmid ptrc99a: laboratory-preserved plasmid, sequence NCBI GenBank: U13872.1

[0032] 3. Plasmid pCas: Laboratory-preserved plasmid, genotype is repA101(Ts)kan P cas -cas9 P araB -RedLacI q ,P trc -sgRNA-pMB1

[0033] 4. Plasmid pTargetF: Laboratory-preserved plasmid, genotype is pMB1 aadA sgRNA-pMB1, spec

[0034] 5. LB solid medium (g / L): peptone 10%, yeast powder 5%, sodium chloride 10%, agar powder 20%.

[0035] 6. LB liquid medium (g / L): peptone 10%, yeast powder 5%, sodium chloride 10%.

[0036] 7. Modified TB medium (g / L): peptone 12%, yeast powder 24%, potassium dihydrogen phosphate, dipotassium hydrogen phosphate 12.54%, glucose 5.

[0037] 8. Fermentation medium (g / L): yeast powder 6, peptone 4, potassium dihydrogen phosphate 13.5, diammonium hydrogen phosphate 4.0, magnesium sulfate heptahydrate 1.4, citric acid 1.7, glucose 20, vitamin B1 0.1, trace element solution 10.0 mL / L, pH 7.0.

[0038] 9. OD 600 Determination: Use deionized water as a blank control and adjust the dilution factor to the OD measured in the cuvette. 600 Between 0.2 and 0.8. After the reading stabilizes, record the reading and multiply it by the dilution factor to get the OD 600 .

[0039] 10. Determination of Residual Sugar Using the SBA-40C Biosensor: Centrifuge the fermentation broth at 12,000 rpm for 10 minutes to separate the supernatant and precipitate. Dilute the supernatant 10-fold with deionized water and vortex to mix thoroughly. Quickly inject 25 μl of standard sample (containing 1 g / L glucose) into the injection port. Wait for the instrument to equilibrate and for the indicator light to stop flashing. Repeat this three or more times. Calibration is considered complete if the readings are essentially consistent. Accurately pipette 25 μl of sample and quickly inject it into the injection port. Record the reading on the instrument display to obtain the residual sugar value.

[0040] 11. Heparin precursor purification: Add an appropriate amount of fermentation broth to a final concentration of 0.02% SDS, heat at 95°C for 15 minutes, and centrifuge at 12,000 g for 10 minutes to remove the precipitate. Add 3-4 volumes of anhydrous ethanol to the supernatant, incubate at -20°C for 4-16 hours, and centrifuge at 12,000 g for 10 minutes to collect the flocculent precipitate. Resuspend in an equal volume of deionized water to obtain the heparin precursor solution.

[0041] 12. Determination of heparin precursor production by the m-hydroxybiphenyl method: Take 50 μL of the above heparin precursor solution and add it to 300 μL of sodium tetraborate sulfuric acid solution (0.478 g sodium tetraborate dissolved in 100 mL of concentrated sulfuric acid) in an ice bath, mix well, heat at 100°C for 5 minutes, add 5 μL of m-hydroxybiphenyl solution (0.15 g m-hydroxybiphenyl dissolved in 5 mg / mL sodium hydroxide solution and fixed to 100 mL), mix well for 5 minutes, and use an enzyme-labeled instrument to measure the 520 nm OD value. Prepare a standard curve using the m-hydroxybiphenyl method using different concentrations of heparin precursor standard solutions. According to the standard curve and the sample OD 520 The yield of heparin precursor was calculated by reading and dilution factor.

[0042] 13. HPLC Assay for Organic Acid Content: Filter 1 mL of fermentation broth supernatant through a 0.22 μm water filter and inject 10-20 μL for HPLC analysis. Detection Method: Aminex HPX-87H column (Bio-Rad), mobile phase 5 mM H₂SO₄, flow rate 0.6 mL / min, column temperature 60°C, UV detector at 210 nm for pyruvate, lactate, and acetic acid. Elution times are approximately 8.9 min, 12 min, and 14.3 min, respectively. Serial dilutions are performed using pyruvate, lactate, and acetic acid standard solutions, respectively. Analyze by HPLC and plot standard curves. Calculate pyruvate, lactate, and acetic acid based on the standard curves.

[0043] Example 1. Construction of ptsG gene knockout plasmid

[0044] The CRISPR / Cas9 knockout system was used to knock out the ptsG gene. First, the knockout plasmid pTargetF-ptsG was constructed. The specific construction process was as follows:

[0045] (1) Through analysis on the website http: / / crispr.mit.edu / , a 20nt N20 sequence complementary to the target sequence of the target gene was selected (see the underlined sequence in the primer in Table 1). The N20 sequence can recognize the target gene region and guide Cas9 to the target part of the DNA. The N20 sequence complementary to the gene target sequence used in the knockout gene ptsG is TAACGATGGCGTATCCGCGC.

[0046] (2) Using plasmid pTargetF as a template, pTargetF-F and pTargetF-R were used to amplify the pTargetF vector. Primers ptsG-F and pTargetF-gRNA-R were used to amplify the N20-containing gRNA sequence of ptsG. The PCR amplification products were verified by electrophoresis and purified.

[0047] (3) The pTargetF vector and the gRNA sequence containing N20 of ptsG were connected using a seamless cloning kit, heated at 55°C for 15 minutes, and then placed on ice.

[0048] (4) The seamless cloning product was transformed into a DH5α competent cell and placed on ice for 30 minutes. The competent cell was then heat-shocked in a 42°C water bath for 90 seconds, placed on ice for 2 minutes, and quickly added with 1 mL of LB liquid medium. The cell was revived at 37°C, 220 rpm for 1 hour, and then spread on an LB plate supplemented with 50 mg / L spectinomycin (Spec) and incubated inverted at 37°C overnight. The transformants were verified by colony PCR using primers JC-F / R. The correctly verified transformants were transferred to an LB liquid test tube supplemented with spectinomycin (Spec), and the plasmid was extracted to obtain the knockout plasmid pTargetF-ptsG.

[0049] Table 1. Primer sequences

[0050]

[0051]

[0052] Example 2: Construction of the gene knockout strain EcNΔptsG

[0053] The CRISPR / Cas9 knockout system was used to knock out the ptsG gene. The specific process is as follows:

[0054] (1) Construction of homology arm knockout fragments: Using the EcN genome as a template, the upstream and downstream homology arms of the ptsG knockout gene were amplified using the homology arm primers (Table 1) ptsG-HA-1 / ptsG-HA-2 and ptsG-HA-3 / ptsG-HA-4, respectively. The PCR amplification product was purified using a DNA gel recovery kit, and the upstream and downstream homology arms were connected using fusion PCR to obtain the ptsG knockout fragment HA.

[0055] (2) Preparation of competent E. coli for electroporation knockout: E. coli carrying the pCas plasmid (EcN / pCas) was inoculated into a 4 ml LB tube and cultured overnight at 30°C with shaking. Then, the overnight culture was transferred to 50 ml LB medium at a 5% inoculum volume and induced with 500 μL 1 M arabinose. The culture was then cultured at 30°C and 220 rpm until the OD 600 =0.6-0.7, remove from ice bath for 15 minutes. Centrifuge at 5000g for 10 minutes at 4°C to collect the cells. Resuspend the cells in 25 ml of pre-chilled sterile deionized water and centrifuge at 5000g for 10 minutes at 4°C to collect the cells. Wash the cells twice with 25 ml of pre-chilled 10% glycerol and centrifuge at 5000g for 10 minutes at 4°C to collect the cells. Resuspend the cells in 1 ml of 10% glycerol and aliquot into 50 μL / tubes for storage at -80°C until use.

[0056] (3) Electroporation transformation of E. coli: Add 100 ng of the knockout plasmid pTargetF-ptsG and 400 ng of the corresponding homology arm knockout fragment HA to the E. coli EcN / pCas competent cells, gently pipette to mix, transfer to a 0.1 cm electroporation cuvette in an ice bath for electroporation (18 kV / cm), then quickly add 1 mL of LB medium to the electroporation cuvette, transfer the bacterial solution to a 1.5 mL EP tube, resuscitate at 30°C, 220 rpm for 1 hour, spread on an LB plate containing 50 mg / L Kan + 50 mg / L Spec, and invert and culture at 30°C overnight. Use primers ptsG-JC-F / ptsG-JC-R to screen the correct transformants by colony PCR.

[0057] (4) Plasmid elimination: The correct knockout transformant was transferred to LB medium supplemented with 50 mg / L Kan and 1 mM IPTG, cultured overnight at 30°C with shaking, and single colonies were isolated by streaking on LB+kan plates. Single colonies sensitive to spectinomycin were screened to obtain a strain that had removed the pTargetF knockout plasmid. The strain was inoculated into LB medium and cultured with shaking at 37°C for 8-12 hours. Single colonies were then isolated by streaking on LB plates, and single colonies sensitive to kanamycin were screened to obtain a strain that had eliminated pCas and pTargetF without resistance mutations, which was named EcN△ptsG. Referring to Examples 1 and 2, manA (NCBIID: WP_001170643.1), wecB (WP_000866670.1), and nagB (WP_001237080.1) gene knockout strains were constructed, respectively, and named EcN△manA, EcN△wecB, and EcN△nagB, respectively.

[0058] Example 3: Construction of recombinant strains

[0059] (1) Construction of plasmid pTrc99a-ACD: Using plasmid pTrc99a as a template, linearized pTrc99a was amplified by PCR using primers ptrc99a-F and ptrc99a-R. Using EcN genome as a template, kfiA, kfiC, and kfiD genes were amplified using primers AF and AR, CF and CR, and DF and DR, respectively (NCBI IDs are WP_000634338.1, WP_001305085.1, and WP_001305084.1, respectively). The kfiA, kfiC, and kfiD gene overexpression plasmid pTrc99a-ACD was then obtained by ligation using a seamless cloning kit.

[0060] (2) Preparation of competent cells: EcN and EcNΔptsG competent cells were prepared according to the method for preparing E. coli electroporation competent cells in Example 2, and 50 μL / tube was dispensed and stored at -80°C for later use.

[0061] (3) Construction of recombinant strains: 100-200 ng of pTrc99a-ACD plasmid was added to EcN and EcN△ptsG electroporation competent cells, mixed evenly, and transformed by electroporation (18 kv / cm). Then, 1 mL of LB medium was added and revived at 37°C for 1 h. The cells were spread on LB solid plates containing 100 μg / mL ampicillin and cultured at 37°C overnight. The transformants were verified by colony PCR. The correct transformants were obtained and transformed into EcN and EcN△ptsG strains with pTrc99a-ACD, named EcN-ACD and EcN△G-ACD, respectively. Similarly, referring to the above method, pTrc99a-ACD was transformed into EcN△manA, EcN△wecB, and EcN△nagB strains, named EcN△M-ACD, EcN△W-ACD, and EcN△N-ACD, respectively.

[0062] Example 4: Fermentation production of heparin precursor by recombinant strains

[0063] Single colonies of EcN, EcN-ACD, EcNΔM-ACD, EcNΔW-ACD, EcNΔN-ACD, and EcNΔG-ACD were inoculated into LB medium (supplemented with 100 μg / mL ampicillin as needed) and cultured at 37°C, 220 rpm for 4-6 hours. A 10% inoculum was then transferred to fermentation medium (supplemented with 100 μg / mL ampicillin as needed) and cultured with shaking at 37°C, 220 rpm for 1-2 hours. IPTG was then added to a final concentration of 0.2 mM, and fermentation was terminated after 20-30 hours. The fermentation broth was treated using the aforementioned method to purify the heparin precursor and determine the residual sugar and heparin precursor yield in the fermentation broth.

[0064] Compared with EcN-ACD, the yield and conversion rates of EcN△M-ACD, EcN△W-ACD, and EcN△N-ACD did not increase, indicating that knocking out the competing pathway genes manA, wecB, and nagB did not improve the yield and conversion rate of heparin precursors. The lactate and acetate contents in the fermentation broth of EcN△G-ACD were significantly lower than those of EcN and EcN-ACD. Meanwhile, the heparin precursor yields of EcN-ACD and EcN△G-ACD were 0.2 g / L and 0.8 g / L, respectively, representing 10-fold and 40-fold increases compared to EcN. Based on the heparin precursor synthase-overexpressing strain EcN-ACD, the strain EcN△G-ACD obtained by knocking out ptsG significantly improved the yield and conversion rate, increasing fourfold compared to EcN-ACD.

[0065] Table 2, strain shake flask fermentation

[0066]

[0067]

[0068] Wherein, — means not determined.

[0069] Example 5: Fermentation of heparin precursors using a 5L fermenter with the recombinant strain

[0070] A single colony of EcN△G-ACD was inoculated into LB medium (supplemented with 100 μg / mL ampicillin) and cultured at 37°C, 220 rpm for 4-6 h. Then, the culture was transferred to modified TB medium (supplemented with 100 μg / mL ampicillin) at a 5% inoculum volume. After shaking culture at 37°C, 220 rpm for 2-4 h, the culture was transferred to a fermentation medium (supplemented with 100 μg / mL ampicillin) at a 10% inoculum volume. In a fermenter, the temperature was 37°C, the stirring speed was 300-1200 rpm, the ventilation volume was 1.5-3 L / min, the dissolved oxygen was controlled at 20-30%, and ammonia was added to control the pH to 6.8-7. After 6-8 h of fermentation, the inducer IPTG was added to a final concentration of 0.2 mM for induction. The glucose concentration in the fermentation broth was controlled at 3-5 g / L. Feed solution (600 g / L glucose, 12 g / L yeast extract, 8 g / L tryptone, 27 g / L KH2PO4, 8 g / L (NH4)2HPO4, 2.8 g / L MgSO4·7H2O, 3.4 g / L citric acid, 0.2 g / L vitamin B1, 20 mL trace metal solution) was added as needed until the end of the fermentation.

[0071] After 60 hours of fermentation, the fermentation broths of different fermentation times were collected, and the heparin precursor was purified and the yield of heparin precursor was detected according to the above method. Figure 2 It can be seen that the yield in the EcN△G-ACD fermentation broth reached 15.9 g / L at 54 h.

Claims

1. A recombinant bacterium producing a heparin precursor, characterized in that: A strain capable of synthesizing heparin precursors was used as the starting strain, and the phosphoenolpyruvate sugar phosphotransferase (PTS) system was knocked out or weakened.

2. The genetically engineered bacterium according to claim 1, wherein The knockout or weakening of the phosphoenolpyruvate sugar phosphotransferase PTS system refers to knocking out or reducing the key component EⅡCB in the PTS system Glc The coding gene ptsG expression.

3. The genetically engineered bacterium according to any one of claims 1 to 2, characterized in that The starting bacteria is a strain having a natural heparin precursor synthesis pathway, or a strain into which exogenous KfiAC or PmHS1 or PmHS2 is introduced on the basis of the UDP-GlcA and UDP-GlcNAc synthesis pathways; preferably, the starting bacteria is Escherichia coli, Pasteurella multocida, Bacillus, or Corynebacterium glutamicum; more preferably, the starting bacteria is Escherichia coli K5, Escherichia coli Nissle 1917, Escherichia coli K12, Escherichia coli BL21, Escherichia coli W3110, or Escherichia coli MG1655.

4. The genetically engineered bacterium according to any one of claims 1 to 3, wherein The genetically engineered bacteria also include enhancing the expression of one, two or three genes of heparin precursor synthase KfiA, KfiC and KfiD, or enhancing the expression of heparin precursor synthase PmHS1 and / or PmHS2; preferably, the heparin precursor synthase KfiA, KfiC and KfiD are derived from Escherichia coli EcN or Escherichia coli K5, and PmHS1 or PmHS2 is derived from Pasteurella multocida.

5. The method for constructing a genetically engineered bacterium according to any one of claims 1 to 4, wherein: The knockout system or knockout gene refers to a method through gene editing, and the weakening system or reducing gene expression refers to reducing the transcription level of the gene by replacing the promoter, or replacing the ribosome binding site, replacing the start codon ATG to GTG or TTG to reduce gene expression at the translation level.

6. The method for constructing a genetically engineered bacterium according to claim 5, wherein: The gene editing method is to use CRISPR / Cas9 knockout system to knock out the gene; more preferably, ptsG The N20 sequence complementary to the gene target sequence used in the present invention is TAACGATGGCGTATCCGCGC.

7. The method for constructing a genetically engineered bacterium according to any one of claims 5 to 6, wherein: The enhanced expression is achieved by introducing an overexpression plasmid, or replacing a strong promoter to enhance gene transcription, or replacing a strong RBS sequence to enhance gene expression, or adding an enhancer to increase the gene transcription level.

8. The method for constructing a genetically engineered bacterium according to claim 7, wherein the overexpression plasmid is pTrc99a, pET, pQE, pBAD, pACYC184, pACYCDuet-1 or pRSFDuet-1.

9. Use of the genetically engineered bacterium according to any one of claims 1 to 4, or the genetically engineered bacterium obtained by the construction method according to any one of claims 5 to 8, in synthesizing a heparin precursor.

10. A method for synthesizing a synthetic heparin precursor, characterized in that: Producing a heparin precursor by fermenting the genetically engineered bacteria according to any one of claims 1 to 4, or the genetically engineered bacteria obtained by the construction method according to any one of claims 5 to 8; optionally, further comprising the step of separating or purifying the produced heparin precursor; Preferably, the method for separating or purifying the heparin precursor is as follows: adding SDS to a final concentration of 0.02% to the fermentation broth, heating at 95°C for 15 minutes, and then centrifuging at 12,000 g for 10 minutes to remove the precipitate; adding 3-4 times the volume of anhydrous ethanol to the supernatant, keeping the mixture at -20°C for 4-16 hours, and centrifuging at 12,000 g for 10 minutes to collect the flocculent precipitate.

Citation Information

Patent Citations

  • Electromagnetic induction heating oven

    CN2483655Y

  • Paint bucket stickers(32)

    CN3209436D

  • Paint bucket stickers(28)

    CN3211488D